This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, The Simons Center for Systems Biology at the Institute for Advanced Study. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 538 
1 out of 621 
1 out of 1 Years Active: 2025
Title: Marta Luksza: Innovator in Cancer Treatment
Introduction
Marta Luksza is a prominent inventor based in New York, NY, who has made significant contributions to the field of cancer treatment. With a focus on immunotherapy, her work aims to enhance the effectiveness of cancer therapies through innovative methodologies.
Latest Patents
Marta Luksza holds a patent titled "Neoantigens and uses thereof for treating cancer." This patent outlines systems and methods for determining the likely responsiveness of a human cancer subject to a checkpoint blockade immunotherapy regimen. The process involves obtaining sequencing reads from cancer samples, determining human leukocyte antigen types, and computing clone fitness scores based on neoantigens. This innovative approach quantifies the likely responsiveness of patients to immunotherapy, potentially improving treatment outcomes.
Career Highlights
Throughout her career, Marta has worked at notable institutions, including the Icahn School of Medicine at Mount Sinai. Her research has focused on advancing cancer treatment methodologies, particularly in the realm of immunotherapy.
Collaborations
Marta has collaborated with esteemed colleagues such as Vinod P Balachandran and Arnold J Levine, contributing to the advancement of cancer research and treatment strategies.
Conclusion
Marta Luksza's innovative work in cancer treatment exemplifies the potential of scientific research to transform patient care. Her contributions through patents and collaborations highlight her commitment to improving therapeutic approaches in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile